Skip to content
Company Analysis

Scilex Holding Company SCLX

A comprehensive view of key metrics, scores, and financial health for Scilex Holding Company

Overview of Scilex Holding Company

SCLX NCM
Healthcare Drug Manufacturers - General Micro Cap
Scilex Holding Company (SCLX), is a Micro Cap company, in the Drug Manufacturers - General industry, last closed at $8.28, about 0.0% overvalued vs fair value, -21.1% 1Y return, ranked 1052/1110 in sector.
$8.28
-6.02%
As of March 13, 2026
Previous close • Vol 90d: 85.7%
52-Week Range
Market Cap
$51.96M
Enterprise Value
$102.95M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Scilex Holding Company.

Top Beats

Quick Facts

Website https://www.scilexholding.com
HQ Palo Alto, CA
Employees 30
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-2
$0
$1
Current: $8.28

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$56.6M
21.1%%
Gross Profit
$39.9M
28.5%%
R&D Expense
$9.6M
-24.4%%
Operating Income (EBIT)
$-70.8M
37.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
17.0%
Good

R&D intensity in normal pharma range (15-25%)

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$10.0M
53.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Scilex Holding Company's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
35
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
15
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing SCLX's balance between Growth (60.2%), Profitability (27.4%), and Safety (12.5%). Growth 60% Safety 12% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

87th percentile vs peers
87
Key Signals
Rev Growth YoY 21.1% 92p Revenue CAGR 3Y 21.8% 92p EPS Growth YoY 57.6% 73p
Strengths
  • Growth performance in top 20% of peers (percentile: 87)
  • Rev Growth Yoy in top 20% of peers (21.1%, 92th percentile)
  • Revenue Cagr 3Y in top 20% of peers (21.8%, 92th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Roic in top 20% of peers (59.1%, 92th percentile)
Risks

No significant risks identified for this axis.

Profitability

39th percentile vs peers
40
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

18th percentile vs peers
18
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Scilex Holding Company.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.29
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info